The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes of patients (pts) with advanced urothelial carcinoma (aUC) treated with immune checkpoint inhibitors (ICIs): Associations with age, race, sex and smoking history.
 
Dimitrios Makrakis
Travel, Accommodations, Expenses - GlaxoSmithKline
 
Rafee Talukder
No Relationships to Disclose
 
Lucia Carril
No Relationships to Disclose
 
Ivan de Kouchkovsky
No Relationships to Disclose
 
Joseph J Park
No Relationships to Disclose
 
Mehmet Asim Bilen
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Exelixis; Genomic Health; Janssen; Nektar; Pfizer; Sanofi; Seagen
Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genentech/Roche (Inst); Genome & Company (Inst); Incyte (Inst); Nektar (Inst); Peloton Therapeutics (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Seagen (Inst); Tricon Pharmaceuticals (Inst); Xencor (Inst)
 
Rana R. McKay
Consulting or Advisory Role - Astellas Medivation; AstraZeneca; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Dendreon; Exelixis; Janssen; Merck; Novartis; Pfizer; Sanofi; Tempus; Vividion Therapeutics
Research Funding - Bayer (Inst); Pfizer (Inst); Tempus (Inst)
 
Neeraj Agarwal
Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AVEO; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Foundation Medicine; Foundation One Inc; Genentech; Janssen Oncology; Lilly; Lilly; Lilly; Medivation/Astellas; MEI Pharma; Merck; Nektar; Novartis; Pfizer; Pfizer; Pharmacyclics; Seagen
Research Funding - Active Biotech (Inst); Amgen (Inst); AstraZeneca (Inst); Bavarian Nordic (Inst); Bayer (Inst); BN ImmunoTherapeutics (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Janssen (Inst); Merck (Inst); Newlink Genetics (Inst); Novartis (Inst); Pfizer (Inst); Prometheus (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Takeda (Inst); TRACON Pharma (Inst)
 
Yousef Zakharia
Consulting or Advisory Role - Amgen; Bayer; Cardinal Health; Castle Biosciences; Clovis Oncology; Eisai; Exelixis; Janssen; Novartis; Pfizer; Roche/Genentech; TTC Oncology
Travel, Accommodations, Expenses - Newlink Genetics
 
Michael E. Devitt
No Relationships to Disclose
 
David James Pinato
Honoraria - Bristol-Myers Squibb; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Da Volterra; Eisai; H3 Biomedicine; Mina Therapeutics; Roche
Speakers' Bureau - Bayer; Falk Pharma; Roche; ViiV Healthcare
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline (Inst); MSD Oncology
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; MSD Oncology
 
Christopher J. Hoimes
Honoraria - Seagen
Consulting or Advisory Role - 2bPrecise; Bristol-Myers Squibb; Eisai; Genentech/Roche; Merck Sharp & Dohme; Prometheus; Seagen
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; Eisai; Genentech/Roche; Seagen
Research Funding - Merck Sharp & Dohme; Merck Sharp & Dohme (Inst)
(OPTIONAL) Uncompensated Relationships - 2bPrecise (Inst)
 
Benjamin Adam Gartrell
No Relationships to Disclose
 
Abhishek Tripathi
Consulting or Advisory Role - EMD Serono; Exelixis; Foundation Medicine; Genzyme; Pfizer
Research Funding - Aravive (Inst); Bayer (Inst); Bayer (Inst); Clovis Oncology (Inst); Corvus Pharmaceuticals (Inst); EMD Serono (Inst); Exact Sciences (Inst); Pfizer (Inst); WindMIL (Inst)
 
Aristotelis Bamias
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Debiopharm Group; MSD; Sanofi
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Ferring; MSD; Pfizer; Roche
Research Funding - AstraZeneca; Bristol-Myers Squibb; Pfizer; Roche
 
Alexandra Drakaki
Employment - ATHOS THERAPEUTICS (I); Attica Sciences (I); Dyania Health (I)
Leadership - ATHOS THERAPEUTICS (I); Attica Sciences (I)
Stock and Other Ownership Interests - Alimera Sciences (I); Athos Therapeutics (I); Attica Sciences; Dyania Health (I); Kyn therapeutics (I); Moderna Therapeutics (I); PROTEAS BIOANALYTICS (I); Urogen pharma (I)
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; DYANIA HEALTH; Exelixis; Janssen; Merck; PACT Pharma; RADMETRIX; Roche/Genentech; Seagen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Infinity Pharmaceuticals (Inst); Jounce Therapeutics (Inst); Kite/Gilead; Merck Sharp & Dohme (Inst); Seattle Genetics/Astellas (Inst)
Patents, Royalties, Other Intellectual Property - My significant other has several patents with UCLA, Harvard Medical School, Athos Therapeutics, Proteas Bioanalytics and ATTICA Sciences (I)
Travel, Accommodations, Expenses - AstraZeneca; Lilly; Seagen
 
Jure Murgic
Honoraria - Astellas Pharma; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Sandoz
Research Funding - Astellas Pharma
Travel, Accommodations, Expenses - BMS; Janssen; Roche
 
Giuseppe Di Lorenzo
No Relationships to Disclose
 
Petros Grivas
Consulting or Advisory Role - 4D Pharma; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Dyania Health; EMD Serono; Exelixis; Foundation Medicine; Genentech; Genzyme; GlaxoSmithKline; Immunomedics; Infinity Pharmaceuticals; Janssen; Merck; Mirati Therapeutics; Pfizer; QED Therapeutics; Roche; Seagen
Research Funding - Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Kure It Cancer Research (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); QED Therapeutics (Inst)
 
Ali Raza Khaki
Stock and Other Ownership Interests - Merck; Sanofi